Danesi R, Mosca M, Boggi U, Mosca F, Del Tacca M
Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, 55 Via Roma, 56126 Pisa, Italy.
Mol Med Today. 2000 Dec;6(12):475-82. doi: 10.1016/s1357-4310(00)01822-0.
The use of immunosuppressive agents in the treatment of transplant rejection and autoimmune disorders is gaining momentum, with significant improvements of both graft and patient survival. The individual response to drugs, however, is variable and unexpected toxicity, or impaired activity might be seen, as a result of molecular determinants that eventually dictate how the individual will respond to immunosuppressive agents. This review addresses a number of issues related to pharmacogenetics, and discusses how this approach might be used to improve the clinical efficacy and tolerability of therapeutic options for the management of organ transplantation and autoimmune disorders in the next decade.
免疫抑制剂在治疗移植排斥反应和自身免疫性疾病方面的应用正日益广泛，移植器官和患者的存活率都有显著提高。然而，个体对药物的反应存在差异，可能会出现意外的毒性反应或活性受损，这是由分子决定因素导致的，这些因素最终决定了个体对免疫抑制剂的反应方式。本综述探讨了一些与药物遗传学相关的问题，并讨论了在未来十年中，这种方法如何用于提高器官移植和自身免疫性疾病治疗选择的临床疗效和耐受性。
